Hemostemix Inc. (CVE:HEM – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.06 and last traded at C$0.06, with a volume of 5100 shares traded. The stock had previously closed at C$0.06.
Hemostemix Trading Down 16.7%
The company has a debt-to-equity ratio of -72.45, a current ratio of 0.49 and a quick ratio of 0.48. The company has a fifty day moving average of C$0.07 and a 200-day moving average of C$0.08. The firm has a market capitalization of C$9.89 million, a PE ratio of -1.72 and a beta of 0.59.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
See Also
- Five stocks we like better than Hemostemix
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
